Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2131 to 2145 of 7707 results

  1. Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]

    Awaiting development [GID-TA11099] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]

    Awaiting development [GID-TA11101] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Children and young people with disabilities and severe complex needs: integrated health and social care support

    Awaiting development [GID-QS10146] Expected publication date: TBC

    Quality standard
    Awaiting development

  4. Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care

    Awaiting development [GID-QS10144] Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Pelvic floor dysfunction

    Awaiting development [GID-QS10129] Expected publication date: TBC

    Quality standard
    Awaiting development

  6. High linear energy transfer radiation for carbon ion beam therapy

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  7. Differential Target Multiplexed Spinal Cord Stimulation (MT742)

      Status ...

    Medical technologies guidance
    Topic selection

  8. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    Awaiting development [GID-TA11025] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]

    Awaiting development [GID-TA11466] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    Awaiting development [GID-TA11491] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development [GID-TA11326] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)

    Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions

    Diagnostics guidance
    Published
    11 November 2015
    View recommendations

    Sections for DG19

  13. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)

    Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer

    Diagnostics guidance
    Published
    9 May 2024
    View recommendations

    Sections for DG58

  14. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146

    Awaiting development [GID-TA11222] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development [GID-TA11161] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development